ReviewVaccines2021
Promising Expectations for Pneumococcal Vaccination during COVID-19.
Review in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 18 citations in OpenAlex.
- Changing Epidemiology of Severe Pneumococcal Pneumonia in Adults at a Tertiary Hospital between 2010 and 2024.Tuberculosis and respiratory diseases · 2026Article
- A multicentre case-control study about effectiveness of pneumococcal vaccination against pneumonia hospitalization in at-risk adults.Pneumonia (Nathan Qld.) · 2026Article
- Vaccine Dispensing in a Section of the Private Healthcare Sector in South Africa (2017-2021).International journal of environmental research and public health · 2025Article
- Coinfection with SARS-CoV-2 among patients with Streptococcus pneumoniae in Casablanca.BMC infectious diseases · 2025Article
- Article
- Interplay between Lung Diseases and Viral Infections: A Comprehensive Review.Microorganisms · 2024Review
- Article
- Expert panel opinion on adult pneumococcal vaccination in the post-COVID era (NAP- EXPO Recommendations-2024).Lung India : official organ of Indian Chest Society · 2024Article
- Article
- Impact of the COVID-19 pandemic on routine vaccine landscape: A global perspective.Human vaccines & immunotherapeutics · 2023Review
- Article
- Influenza and Pneumococcal Vaccination and the Risk of COVID-19: A Systematic Review and Meta-Analysis.Diagnostics (Basel, Switzerland) · 2022Review
- Black Fungus and beyond: COVID-19 associated infections.Clinical imaging · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The emergence of new viral infections has increased over the decades. The novel virus is one such pathogen liable for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, popularly known as coronavirus disease 2019 (COVID-19). Most fatalities during the past century's influenza pandemics have cooperated with bacterial co/secondary infections. Unfortunately, many reports have claimed that bacterial co-infection is also predominant in COVID-19 patients (COVID-19 associated co/secondary infection prevalence is up to 45.0%). In the COVID-19 pandemic,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.